

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/709,739	05/26/2004	Itzhak Bentwich	050992.0302.00USCP	3738
37808 7590 01/09/2008 ROSETTA-GENOMICS		EXAMINER		
c/o PSWS			SCHNIZER, RICHARD A	
700 W. 47TH STREET SUITE 1000 KANSAS CITY, MO 64112			ART UNIT	PAPER NUMBER
		1635		
			MAIL DATE	DELIVERY MODE
			01/09/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		T	I A U 44 >			
		Application No.	Applicant(s)			
		10/709,739	BENTWICH ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Richard Schnizer, Ph. D.	1635			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE in a sign of time may be available under the provisions of 37 CFR 1.11 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period varie to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be ting will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. mely filed  the mailing date of this communication. ED (35 U.S.C. § 133).			
Status		·				
1)🖂	Responsive to communication(s) filed on 28 N	<u>ovember 2007</u> .				
2a)□	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.					
3)	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
4)⊠	4)⊠ Claim(s) <u>26,31,33 and 35-40</u> is/are pending in the application.					
.,	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)	5) Claim(s) is/are allowed.					
6)⊠	☐ Claim(s) <u>26,31,33 and 35-40</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)[	Claim(s) are subject to restriction and/o	r election requirement.				
Applicat	ion Papers					
9)	The specification is objected to by the Examine	er.				
	The drawing(s) filed on 26 May 2004 and 02 Ja		ed or b)  objected to by the			
Examine			•			
	Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)	The oath or declaration is objected to by the Ex	caminer. Note the attached Office	e Action or form PTO-152.			
<b>Priority</b>	under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* (	See the attached detailed Office action for a list	or the certified copies not receive	eu.			
	4.3		•			
Attachmer	nt(s) ce of References Cited (PTO-892)	4) Interview Summary	v (PTO-413)			
	ce of References Cited (PTO-692) ce of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	Date			
3) Infor	mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	5) Notice of Informal (6) Other:	Patent Application			

10/709,739 Art Unit: 1635

### **DETAILED ACTION**

An amendment was received and entered 11/28/07.

Claims 23-25, 27-30, 32, and 34 were canceled, and claims 35-40 were added.

Claims 26, 31, 33, and 35-40 are pending and under consideration.

Rejections not reiterated are withdrawn.

This Action is NON-FINAL due to the indication in the previous Action that SEQ ID NO: 118171 was free of the prior art. Nucleic acids consisting of SEQ ID NO: 118171, are considered to be obvious for the reasons set forth below.

### Oath/Declaration

The oath filed 11/28/07 overcame the previous objection.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 26, 31, and 33 are rejected under 35 U.S.C. 102(e) as being anticipated by Pfeffer et al (US 20050222067).

Application/Control Number:

10/709,739 Art Unit: 1635

Pfeffer taught SEQ ID NO: 82 which is identical to instant SEQ ID NO: 4204050. See Table A2 at page 5 of Pfeffer. Pfeffer also taught vectors comprising SEQ ID NO: 82. See paragraphs 31-33 and claims 70 and 72. Note that SEQ ID NO: 82 is considered to be a probe comprising the sequence of instant SEQ ID NO: 4204050, as are the vectors of '067 claims 70 and 72.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 35-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pfeffer et al (US 20050222067).

Pfeffer taught SEQ ID NO: 82 which is identical to instant SEQ ID NO: 4204050. See Table A2 at page 5 of Pfeffer.

Pfeffer did not explicitly teach a sequence consisting of instant SEQ ID NOS: 117937 or 118171. However, Pfeffer did explicitly disclose instant SEQ ID NO: 4204050, which comprises instant SEQ ID NOS: 117937 or 118171, and Pfeffer also fairly taught isolated molecules comprising 10-50 bases of SEQ ID NO: 82, and vectors comprising these sequences. See paragraphs 17, 18, and 31-33.

It would have been obvious to one of ordinary skill in the art at the time of the invention to make any 10-50 base fragment of SEQ ID NO: 82 of Pfeffer for use as an

Application/Control Number:

10/709,739 Art Unit: 1635

inhibitory RNA molecule because Pfeffer makes this suggestion at paragraphs 17 and 18. Further Pfeffer discloses a 22-base fragment that differs from instant SEQ ID NO: 117937 by beginning and ending 1 base earlier in the sequence of SEQ ID NO: 82 than does instant SEQ ID NO: 117937 (see the first sequence disclosed in Table A2, i.e. SEQ ID NO: 71), so it is clear that one of ordinary skill would have considered 22 base fragments of SEQ ID NO: 82 as inhibitory RNA molecules. In so doing one would have arrived at all forty-six possible 22 base fragments of SEQ ID NO 82. Thus the invention as a whole was prima facie obvious.

### Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Richard Schnizer, whose telephone number is 571-272-0762. The examiner can normally be reached Monday through Friday between the hours of 6:00 AM and 3:30. The examiner is off on alternate Fridays, but is sometimes in the office anyway.

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, J. Douglas Schultz, can be reached at (571) 272-0763. The official central fax number is 571-273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of

Application/Control Number:

10/709,739 Art Unit: 1635 Page 5

document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Richard Schnizer, Ph.D.

Primary Examiner

Art Unit 1635